Drugs for the 50+ worth US$64 billion by 2015 – USA

Medicines used for wrinkle reduction will exhibit the greatest growth at 17.7% per year, followed by drugs used to address Alzheimer’s disease at 12.1% per year.

According to a report from Fuji-Keizai USA, “Drugs for the Diseases of Aging – US Markets and Trends for Prescription Medicines Used Predominantly by Persons Age 50 and older” in 2010, sales of  drugs used exclusively persons age 50 and older were $50 billion. Through 2015, sales will expand by 5.3% per year to reach more than $64 billion.

This report for sale at US$1,495 reviews, analyses and sizes the markets for prescription medicines used to address diseases and conditions that predominantly affect persons age 50 and older. It focuses on the large U.S. market, with five-year revenue projections to 2015. It also presents merger and acquisition activity, research and development (R&D) initiatives and venture capital activity for current and emerging drug developers.

Specific market segments examined include many of the effects of ageing monitored by our AF Tool.

  • Alzheimer’s disease
  • Arthritis
  • Cancer
  • Cardiovascular disease
  • Diabetes
  • Erectile dysfunction
  • Eye disease
  • Hair loss
  • High cholesterol
  • Hypertension
  • Kidney disease
  • Osteoporosis
  • Parkinson’s disease
  • Stroke
  • Wrinkles